Abstract:Objective To explore the effects of dialysate calcium concentrations (DCC)on risks of adverse reactions occurred in maintenance hemodialysis patients during dialysis. Methods The subjects were end-stage renal disease (ESRD)patients in stable condition who were treated with maintenance dialysis in the First Affiliated Hospital,Zhejiang University from June to October 2016. According to the DCC,the patients were randomly divided into 3 groups,the 1.25 mmol/L group,the 1.35 mmol/L group,and the 1.50 mmol/L group;the observation time was 12 weeks. The urea clearance index Kt/V,urea reduction rate (URR),mean arterial pressure before and after dialysis,the serum calcium,serum phosphorus,intact parathyroid hormone (iPTH),and alkaline phosphatase (ALP)levels before and after dialysis,and the incidence of muscle spasm,nausea and vomiting,headache,chest tightness,and arrhythmia in hemodialysis patients in the 3 groups were compared. Results A total of 273 patients entered the study,including 159 males and 114 females with ages from 25 to 83 years and average age of (52 ± 9)years. Each of the 1.25 mmol/L,1.35 mmol/L,and 1. 50 mmol/L groups comprised 91 patients. The differences of baseline data in patients in the 3 groups were not statistically significant (P＞0.05). After 12 weeks of hemodialysis,the differences of Kt/V and URR in patients in the 3 groups were not statistically significant (all P＞0.05);the differences of the mean arterial pressures in patients in the 1.25 and 1.35 mmol/L groups [(102 ± 9)and (103 ±11)mmHg,respectively]were not statistically significant (all P ＞0.0.5);the mean arterial pressure in the patients in the 1.50 mmol/L group was higher than that before hemodialysis [(120 ± 12) mmHg vs.(103 ± 9)mmHg,P＜0.01]and was higher markedly than that in 1.25 and 1.35 mmol/L groups (all P＜0.01);the serum calcium level in patients in the 1.25 mmol/L group was lower than that before hemodialysis [(1.94 ± 0.31)mmol/L vs.(2.24 ± 0.18)mmol/L,P＜0.01];the serum calcium level in the patients in the 1.50 mmol/L group was higher than that before hemodialysis [(2.54 ± 0.18) mmol/L vs.(2.24 ± 0.17)mmol/L,P＜0.01];the iPTH and ALP levels in patients in the 1.25 mmol/L group were higher than those before hemodialysis [(356 ± 68)U vs.(291 ± 49)U,(443 ± 45)U vs. (343 ± 58)U,all P ＜0.01]. During dialysis,the incidence of muscle spasm in patients in the 1.25 mmol/L group was higher than that in the 1.35 mmol/L and 1.50 mmol/L groups [14.28% (13/91)vs. 5.49% (5/91)and 4.39% (4/91),all P ＜0.05];the incidence of headache in patients in the 1.50 mmol/L group was higher than that in the 1.25 mmol/L and 1.35 mmol/L groups [14.28% (13/91)vs. 3.30% (3/91)and 5.49% (5/91),P ＝0.01 and P ＜0.05]. The differences in incidences of chest tightness,arrhythmia,nausea and vomiting were not statistically significant (all P＞0.05). Conclusion The dialysate with calcium concentration of 1.35 mmol/L may reduce the incidence of muscle spasm,does not increase the incidence of hypertension and headache,and effectively reduce the risk of adverse reactions in maintenance hemodialysis patients,while ensuring the adequacy of dialysis.

Oral activated charcoal decreases serum phosphate level and calcium phosphorus products in dialysis patients with refractory hyperphosphataemia

Active charcoal combined with zhubarb containing preparation as an adjuvant measure to control hyperphosphatemia in patients on dialysis

In vitro phosphate-binding ability of calcium-based agents is augmented by co-administration of activated charcoal.

Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study.

Lanthanum Carbonate for the Treatment of Hyperphosphatemia in Ckd 5d: Multicenter, Double Blind, Randomized, Controlled Trial in Mainland China

Calcium and Phosphonium Metabolism in Peritoneal Dialysis Patients with Different Dialysates

Randomized Controlled Trial of Dialysate Calcium Concentrations on Risks of Adverse Reactions in Hemodialysis Patients During Dialysis

THE EFFECTS OF CALCIUMCARBONATE/MAGNESIUM CARBONATE COMBINATION CHEWABLE TABLETS IN COMPARISON TO CALCIUM CARBONATE TABLETS ON PHOSPHATE BINDING IN HEMODIALYSIS PATIENTS WHO ARE TAKING PROTON PUMP INHIBITORS

Effect of Short-Term Low-Protein Diet Supplemented with Keto Acids on Hyperphosphatemia in Maintenance Hemodialysis Patients

The absorption of dietary phosphorus and calcium in hemodialysis patients

Mineral and Bone Disorder in Chinese Dialysis Patients: a Multicenter Study

Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease-mineral bone disorder parameters in dialysis patients

Effect of iron as a new type of phosphate binder in hemodialysis patients

Relationship between Gut Microbiota and Phosphorus Metabolism in Hemodialysis Patients: A Preliminary Exploration

Effects of lanthanum carbonate on serum phosphorus in maintenance hemodialysis patients receiving calcitriol pulse therapy due to secondary hyperparathyroidism

Clinical Research of Hemodialysis Combined with Colon Dialysis in Uremic Patients with Hyperphosphatemia

Effect of Colestilan on Serum Phosphorus in Dialysis Patients: A Meta-Analysis of the Literature.

Effect of Dietary Phosphate Restriction in Pre-Dialysis Chronic Kidney Disease Patients with Hyperphosphataemia in Southern Nigeria

Additional Reduction in Serum Phosphorus Levels by Pulverized Lanthanum Carbonate Chewable in Hemodialysis Patients

Effect of Combining Different Calcium Concentration Dialysate on Calcium Balance in Peritoneal Dialysis Patients

The effect of phosphate binder therapy with sucroferric oxyhydroxide on calcification propensity in chronic haemodialysis patients: a randomized, controlled, crossover trial